Report: cancer drug spend rises, metabolic scripts jump

Share this article:

Spending on cancer treatments is rising much faster than for other common pharmaceuticals, a report issued on Monday said.
Spending on cancer and related medications rose by 15 percent in 2004, nearly double the increase in 2003, according to a report from Medco Health Solutions.
Increased use of Novartis' Gleevec and AstraZeneca's Iressa accounted for most of the jump, the report said.
The report also found that Americans with metabolic syndrome account for $4 of every $10 spent on prescription drugs for adults.
Annual prescription costs for people 20 and older with metabolic syndrome averaged $4,116 last year, 4.2 times the average amount spent on drugs for that age group, the Medco
report said.
Adult use of medication for metabolic syndrome -- a condition marked by excess abdominal fat, diabetes, high blood pressure and cholesterol problems -- jumped 36 percent between 2002 and 2004.
Medco reached its findings by examining prescription records from a random sample of 2 million clients.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.